share_log

Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207.

Benzinga ·  Nov 16 01:08
Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment